angioimmunoblastic T-cell lymphoma


Also found in: Acronyms, Wikipedia.

angioimmunoblastic T-cell lymphoma

rare subtype of lymphoma characterized by generalized lymphadenopathy, prominent systemic symptoms, fever, weight loss, skin rash, polyclonal gammopathy, circulating immune complexes and autoantibodies, and a tendency to infection complication. Previously referred to as angioimmunoblastic lymphadenopathy with dysproteinemia (AILD). Diagnosis is often difficult because of the varying clinicopathologic picture. Fewer than one third of the patients can be expected to have long-term remissions even after multiagent chemotherapy. Complete remissions have been reported after the use of interferon-α and cyclosporine.

angioimmunoblastic T-cell lymphoma

A lymphoma affecting the elderly characterised by generalised lymphadenopathy and systemic symptoms.
 
DiffDx
Drug reaction (e.g., antibiotics, phenytoin), T-cell-rich diffuse large B cell lymphoma, classical Hodgkin lymphoma, angioimmunoblastic lymphadenopathy with dysproteinaemia, peripheral T-cell lymphoma (undifferentiated).
References in periodicals archive ?
The gene expression profile of nodal peripheral T-cell lymphoma demonstrates a molecular link between angioimmunoblastic T-cell lymphoma (AITL) and follicular helper T (TFH) cells.
Expression of CXCL13 by neoplastic cells in angioimmunoblastic T-cell lymphoma (AITL): a new diagnostic marker providing evidence that AITL derives from follicular helper T cells.
Sustained remission from angioimmunoblastic T-cell lymphoma induced by alemtuzumab.
9) The findings were that angioimmunoblastic T-cell lymphomas were more common in Taiwan, whereas adult T-cell leukemia/lymphomas were more prevalent in Japan (P = .
A snapshot of the global therapeutic scenario for Angioimmunoblastic T-Cell Lymphoma (AILT)/Immunoblastic Lymphadenopathy.
A review of the Angioimmunoblastic T-Cell Lymphoma (AILT)/Immunoblastic Lymphadenopathy products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
Coverage of the Angioimmunoblastic T-Cell Lymphoma (AILT)/Immunoblastic Lymphadenopathy pipeline on the basis of route of administration and molecule type.
Identify and understand important and diverse types of therapeutics under development for Angioimmunoblastic T-Cell Lymphoma (AILT)/Immunoblastic Lymphadenopathy.
Data from 45 patients treated on the single-arm, dose-escalation study of SGN-35 were presented, including 42 with Hodgkin lymphoma, two with systemic anaplastic large cell lymphoma (ALCL) and one with angioimmunoblastic T-cell lymphoma.
Data from 39 patients treated on the single-arm, dose-escalation study of SGN-35 were presented at ASCO, including 36 with Hodgkin lymphoma, two with systemic anaplastic large cell lymphoma (ALCL) and one with angioimmunoblastic T-cell lymphoma.
This includes peripheral and angioimmunoblastic T-cell lymphomas of which 75% are CD4 positive and anaplastic large cell lymphomas of which 20% are CD4 positive.